Bamlanivimab is indicated for:
Irrespective of gender only Adults (18 years old or older)
Treatment of mild-to-moderate COVID-19 in patients aged ≥12 years who weigh ≥40 kg with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Patient selection
High-risk defined as meeting at least 1 of these criteria:
BMI ≥35
Chronic kidney disease
Diabetes
Immunosuppressive disease
Receiving immunosuppressive treatment
Age ≥65 years
Age ≥55 years and have cardiovascular disease, hypertension, or COPD/chronic respiratory disease
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adolescents (12 years - 18 years old)
Treatment of mild-to-moderate COVID-19 in patients aged ≥12 years who weigh ≥40 kg with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
Patient selection
High-risk defined as meeting at least 1 of these criteria:
Chronic kidney disease
Diabetes
Immunosuppressive disease
Receiving immunosuppressive treatment
Additional high-risk factors in patients aged 12-17 years:
BMI ≥85th percentile for their age and sex based on CDC growth charts
Sickle cell disease
Congenital or acquired heart disease
Neurodevelopmental disorders (eg, cerebral palsy)
Medical-related technological dependence (eg, tracheostomy, gastrostomy, positive-pressure ventilation [not related to COVID-19])
Asthma, reactive airway diease, or other chronic respiratory disease requiring daily medication for control
For this indication, the medical literature mentions below treatments (click for details):